Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)
China · Delayed Price · Currency is CNY 6.31
-0.01 (-0.16%)
At close: Feb 6, 2026
SHE:002252 Revenue
Shanghai RAAS Blood Products had revenue of 2.14B CNY in the quarter ending September 30, 2025, with 3.72% growth. This brings the company's revenue in the last twelve months to 7.95B, down -4.67% year-over-year. In the year 2024, Shanghai RAAS Blood Products had annual revenue of 8.18B with 2.67% growth.
Revenue (ttm)
7.95B
Revenue Growth
-4.67%
P/S Ratio
5.24
Revenue / Employee
2.37M
Employees
3,350
Market Cap
41.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.18B | 212.50M | 2.67% |
| Dec 31, 2023 | 7.96B | 1.40B | 21.27% |
| Dec 31, 2022 | 6.57B | 2.28B | 53.16% |
| Dec 31, 2021 | 4.29B | 1.53B | 55.26% |
| Dec 31, 2020 | 2.76B | 176.70M | 6.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmaron Beijing | 13.54B |
| Chongqing Zhifei Biological Products | 10.91B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Haisco Pharmaceutical Group | 4.27B |
| Hualan Biological Engineering | 4.27B |
| Xiamen Amoytop Biotech | 3.34B |